A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)

Summary

This trial is conducted in Asia. The aim of this trial is to confirm the efficacy of insulin degludec/liraglutide in controlling glycaemia in Chinese subjects with type 2 diabetes mellitus inadequately controlled on oral antidiabetic agents

Timeline

Start

2017-05-26

Primary completion

2019-06-14

Completion

2019-07-13

Outcome

Met primary endpoint

registry analysis (superiority test); Insulin Degludec/Liraglutide vs Liraglutide; p <0.0001; Mean treatment difference -0.63 (95% CI -0.76 to -0.49); ANCOVA NCT03172494 ↗

paper indicating noninferiority for IDegLira vs degludec and superiority vs liraglutide. PMID 35762390 ↗

Publications

• Results Wang W, Agner BFR, Luo B, Liu L, Liu M, Peng Y, Qu S, Stachlewska KA, Wang G, Yuan G, Zhang Q, Ning G. DUAL I China: Improved glycemic control with IDegLira versus its individual components in a randomized trial with Chinese participants with type 2 diabetes uncontrolled on oral antidiabetic drugs. J Diabetes. 2022 Jun;14(6):401-413. doi: 10.1111/1753-0407.13286.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Insulin degludec/liraglutide	Unknown	—	Subcutaneous
Subject	Liraglutide	Peptide	—	Subcutaneous
Subject	insulin degludec	Protein / enzyme biologic	—	Subcutaneous

Indications